glp-1 and beta blockers Bridging the gap between GLP1-receptor agonists cardiovascular outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology Unlocking the multifaceted roles of

Adequate sleep supports the body's natural circadian rhythms, which influence hormone secretion patterns throughout the day

The coverage pullback reflected an industry-wide reassessment of GLP-1 weight loss drug benefits

Within the first week or two, some individuals may notice slight changes, such as feeling fuller more quickly or a mild reduction in appetite, but these effects typically become more pronounced as the dose is gradually increased

previously called nonalcoholic steatohepatitis [NASH]

NCT05520775: Semaglutide for Alcohol Use Disorder Status: Underway This is an early-Phase II human trial using a randomized, placebo-controlled, dose-ranging design to investigate the effects of semaglutide, a GLP-1 receptor agonist, on alcohol-related outcomes in adults with alcohol use disorder

K.AgarwalS.TripathiA.ChaturvediR